

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>McCracken Nigel William</u> <hr/> (Last) (First) (Middle) BIOCITY GLASGOW BO'NESS ROAD NEWHOUSE LANARKSHIRE <hr/> (Street) MOTHERWELL X0 ML1 5UH LANARKSHIRE <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/18/2026	3. Issuer Name and Ticker or Trading Symbol <u>Virax Biolabs Group Ltd [VRAX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;">Chief Operating Officer</p>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Options (right to buy)	(1)	09/01/2033	Ordinary Shares	20,000	3.6	D	
Stock Options (right to buy)	(2)	04/18/2034	Ordinary Shares	50,000	0.68	D	
Stock Options (right to buy)	(3)	04/08/2035	Ordinary Shares	20,584	0.88	D	
Stock Options (right to buy)	(4)	04/08/2035	Ordinary Shares	29,416	0.88	D	

Explanation of Responses:

- On September 1, 2023, the Company granted 20,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on September 1 of each of 2024, 2025 and 2026. The vested portions of such options will become exercisable upon vesting.
- On April 18, 2024, the Company granted 50,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026 and 2027. The vested portions of such options will become exercisable upon vesting.
- On April 8, 2025, the Company granted 20,584 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.
- On April 8, 2025, the Company granted 29,416 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.

Remarks:

The Reporting Person submitted a completed Form ID application and the related required documents before March 18, 2026, did not receive access to the Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system (EDGAR) by March 18, 2026, and is filing this report as soon as possible after receiving EDGAR access.

/s/ Nigel McCracken 03/20/2026
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.